Trial Profile
A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF PF 04360365 IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs Ponezumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 17 Mar 2012 Additional location (France) added as reported by European Clinical Trials Database.
- 27 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.